Tonix reverses into US public shell, raising $1.1 million and questions
This article was originally published in Scrip
Executive Summary
Tonix Pharmaceuticals, a specialty pharma company focused on CNS disorders and based in New York City, has completed a reverse merger transaction through a share exchange agreement with publicly traded Tamandare Explorations Inc. Through a share exchange, the shareholders of Tonix acquired control of Tamandare.